Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

Journal of Thoracic Oncology

Volumn 12, Issue 1, 2017, Pages 137-140

  Ou, Sai Hong Ignatius ^a   Young, Lauren ^b   Schrock, Alexa B ^b   Johnson, Adrienne ^b   Klempner, Samuel J ^c   Zhu, Viola W ^a,d   Miller, Vincent A ^b   Ali, Siraj M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Circulating tumor DNA; Crizotinib; MET exon 14 skipping; MET Y1230C; Resistance mutation

Indexed keywords

CARBOPLATIN; CHLOROPLAST DNA; CRIZOTINIB; CYTOKERATIN 7; PACLITAXEL; PLASMID DNA; THYROID TRANSCRIPTION FACTOR 1; DNA; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CASE REPORT; DRUG RESPONSE; ENDOBRONCHIAL ULTRASONOGRAPHY; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOGENESIS; LUNG TUMOR; LYMPHADENOPATHY; MET ONCOGENE; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PROTO ONCOGENE; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; VASCULAR CERVICAL METASTASIS; AGED; BLOOD; BRAIN TUMOR; DRUG RESISTANCE; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES;

EID: 85015316213     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.09.119     Document Type: Article

References (16)

1. 1 Van Der Steen, N., Giovannetti, E., Pauwels, P., et al. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol 11 (2016), 1423–1432.
2. 2 Drilon, A.E., Camidge, D.R., Ou, S.H.I., et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 34(suppl), 2016, 108.
3. 3 Heist, R.S., Sequist, L.V., Borger, D., et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol 11 (2016), 1242–1245.
4. 4 Cui, J.J., Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem 57 (2014), 4427–4453.
5. 5 Qi, J., McTigue, M.A., Rogers, A., et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71 (2011), 1081–1091.
6. 6 Tiedt, R., Degenkolbe, E., Furet, P., et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71 (2011), 5255–5264.
7. 7 Hughes, P.E., Rex, K., Caenepeel, S., et al. In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models. Mol Cancer Ther 15 (2016), 1568–1579.
8. 8 Yan, S.B., Peek, V.L., Ajamie, R., et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs 31 (2013), 833–844.
9. 9 Rosell, R., Molina, M.A., Costa, C., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17 (2011), 1160–1168.
10. 10 Pennacchietti, S., Cazzanti, M., Bertotti, A., et al. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res 74 (2014), 6598–6609.
11. 11 Turke, A.B., Zejnullahu, K., Wu, Y.L., et al. Preexistence of clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17 (2010), 77–88.
12. 12 Schrock, A.B., Frampton, G.M., Suh, J., et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 11 (2016), 1493–1502.
13. 13 Costa, D.B., Kobayashi, S., Pandya, S.S., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29 (2011), e443–e445.
14. 14 Klempner, S.J., Borghei, A., Hakimian, B., Ali, S.M., Ou, S-HI, Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases. J Thorac Oncol 12 (2017), 152–156.
15. 15 Gainor, J.F., Dardaei, L., Yoda, S., et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6 (2016), 1118–1133.
16. 16 Caumont, C., Veillon, R., Gros, A., et al. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma. Lung Cancer 92 (2016), 15–18.